This is a preview of subscription content, log in via an institution to check access.
Reference
Maeda A, et al. Serum concentration of the CKD4/6 inhibitor abemaciclib, but not of creatinine, strongly predicts hematological adverse events in patients with breast cancer: a preliminary report. Investigational New Drugs 39: 272-277, No. 1, Feb 2021. Available from: URL: http://doi.org/10.1007/s10637-020-00994-3
Rights and permissions
About this article
Cite this article
Abemaciclib. Reactions Weekly 1866, 12 (2021). https://doi.org/10.1007/s40278-021-99708-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-99708-x